Developing an mHealth Application to Improve Cancer Chemotherapy Symptom Management
Trial Snapshot
- Phase
- Not Applicable
- Status
- Completed
- Sponsor
- University of Michigan
- Enrollment
- 16
- Locations
- 2
- Primary Endpoint
- Patient Satisfaction and Usability of the MyChemoCare Application
Study Overview
Brief Summary
This research project addresses critical gaps in cancer symptom management through the creation of a mobile chemotherapy symptom management application. This application will assess for the presence and severity of common chemotherapy side-effects and provide personally tailored symptom-related video and narratives to enhance self-management of cancer and treatment-related symptoms. This study will examine patient acceptance and use of this mHealth application (called MyChemoCare) in a prospective trial of cancer patients (n=60) who are receiving chemotherapy for colorectal cancer at the University of Michigan Comprehensive Cancer Center.
Study Design
- Study Type
- Interventional
- Allocation
- Na
- Intervention Model
- Single Group
- Primary Purpose
- Supportive Care
- Masking
- None
Eligibility Criteria
- Ages
- 18 Years to 80 Years (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Diagnosed with colon or rectal cancer
- •Expected to live at least 6 months
- •Initiating chemotherapy for the first time in their treatment history
- •Physically and mentally able to participate
- •Able to read English
- •Willing and able to sign informed consent
Exclusion Criteria
- •A treatment plan that does not include cytotoxic chemotherapy for colon or rectal cancer
- •A medical history that includes cancer with the exception of in situ cancers of the cervix and basal cell cancers of the skin
- •A current diagnosis that includes multiple cancers (this does not exclude metastatic disease)
- •Received prior cytotoxic chemotherapy for any reason
- •A diagnosed psychiatric disorder
Outcomes
Primary Outcomes
Patient Satisfaction and Usability of the MyChemoCare Application
Time Frame: 8 weeks post enrollment
The investigators will use a 9-item survey developed by Dr. An to assess patients' experiences using the MyChemoCare app. This result is the mean of the the survey items (with opposite items reversed). The scale was scored from 0 = Strongly disagree to 6 = Strongly agree.
Patient Retention and Engagement With the MyChemoCare Application
Time Frame: 8 weeks post-enrollment
Patient retention is defined as the number of patients who completed the 8-week study through the final evaluation. Engagement with the MyChemoCare application was measured as number of patients who checked in at least once per week of the study.
Secondary Outcomes
- Symptom Burden Reduction(8 weeks post enrollment)
- Increased Mastery of Cancer and Chemotherapy Symptoms(8 weeks post enrollment)
- Physician Use of the Study Feedback Mechanism(8 weeks post-enrollment)
- Improved Quality of Life(Baseline and 8 weeks post enrollment)
Investigators
Lawrence C. An
Associate Professor of Internal Medicine
University of Michigan